Previous 10 | Next 10 |
Should Investors Be Watching These Top Biotech Stocks Right Now? Biotech stocks are among the most active stocks in the stock market today. Namely, a key factor contributing to this now would be the latest update on the Covid pandemic. Over the Thanksgiving weekend, global h...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The omicron variant of Covid-19 has sent several pharmaceutical companies flying higher this past week, such as Moderna (NASDAQ: MRNA ) and Pfizer (NYSE: PFE ). Today, shares of Adagio Therapeutics (NASDAQ: ...
Adagio Therapeutics CEO Tillman Gerngross said Monday that its anti-COVID antibody was specifically designed to remain effective against variants of the disease. In an interview with CNBC, the chief executive of Adagio Therapeutics (NASDAQ:ADGI) added that early signs suggest it will countera...
Twitter (NYSE:TWTR) grabbed the spotlight in midday trading on Monday. News that CEO Jack Dorsey is giving up the top position at the company put mild pressure on the stock. COVID-related stocks also remained volatile during the day. This included massive gains for NRx Pharmaceuticals (NASDAQ...
Gainers: Krystal Biotech (NASDAQ:KRYS) +118%, Petros Pharmaceuticals (NASDAQ:PTPI) +96%, Adagio Therapeutics (NASDAQ:ADGI) +69%, iSpecimen (NASDAQ:ISPC) +50%, cbdMD (NYSE:YCBD) +31%. Losers: Fennec Pharmaceuticals (NASDAQ:FENC) -51%,...
Companies that produce mRNA vaccines -- Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) -- as well as companies that produce certain anti-virals -- Adagio (NASDAQ:ADGI) and Pfizer -- are poised to benefit from the Omicron COVID-19 variant, according to Morgan Stanley. Analyst Matthew Harrison has...
Adagio Therapeutics is working on the development of differential antibodies for the prevention and treatment of COVID-19. A new COVID-19 variant is sending fears throughout the stock market. COVID-19 treatment stocks such as Adagio Therapeutics have received a nice boost. Thr...
Adagio Therapeutics (NASDAQ:ADGI) soars 24.2% premarket after providing information related to the potential of its lead SARS-CoV-2 antibody, ADG20, to address the Omicron variant. “Due to the highly conserved and immunorecessive nature of the epitope recognized by ADG20, we ...
Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing ADG20 EUA submissions planned for prevention and treatment of COVID-19 in mid-2022 Inventory build continues in anticipation of EUA in second half of 2022, with 4 million ...
A newly detected coronavirus variant in Africa created panic and sparked a market selloff in the holiday-shortened week. However, the developers of COVID-19 vaccines and therapeutics advanced while several common stock offerings pressured decliners. Despite the outperformance of biotech stock...
News, Short Squeeze, Breakout and More Instantly...
Adagio Therapeutics Inc. Company Name:
ADGI Stock Symbol:
NASDAQ Market:
WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that as part of the annual reconstitution of the Russell stock indexes, Invivyd will be included in ...
Pseudovirus in vitro neutralization data show continued neutralizing activity of VYD222 (pemivibart) against the KP.1.1 FLiRT and KP.3 SARS-CoV-2 variants, virus selections representative of current dominant strains and the most recent FLiRT-containing viruses Invivyd’s new data is...
WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Heal...